Acceptance and Commitment Therapy for Body Dissatisfaction: A Systematic Review and Meta-Analysis
Abstract
INTRODUCTION: Body dissatisfaction (BD) is increasing internationally and is associated with a range of physical and psychological negative outcomes, including eating disorders (ED). As a result, there is a great need to identify treatments that reduce BD to intervene and prevent these outcomes. Acceptance and commitment therapy (ACT) has been employed for body image and weight concerns. However, there is limited data on the efficacy of ACT in reducing BD.
OBJECTIVE: To evaluate the efficacy of ACT on measures of BD in those with or without a diagnosable ED.
METHODS: A systematic review and meta-analysis were conducted, including 12 studies that utilized individual, group, or online self-help ACT interventions targeting BD (N = 825; analyzed at the end of interventions N = 741).
RESULTS: ACT was efficacious in decreasing BD compared to control groups with a significant medium effect size in the full sample (k = 12, g = 0.556, 95% CI = [0.35, 0.77], p < 0.001, I2 = 45.61). The strongest effect sizes were produced by subgroups of participants who were at high risk for EDs (k = 6, g = 0.631, p < 0.001), and those who received ACT via online self-help forums (k = 3, g = 0.563, p < 0.005). A majority of studies (75%) had low to medium risk of bias. The mean dropout rate across ACT interventions was 23.51%.
DISCUSSION: These results demonstrate that ACT is efficacious in BD reduction, particularly in those with high BD, at risk for developing EDs, and in the form of online…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 825 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.